Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.2500
-0.0107 (-4.10%)
At close: Mar 17, 2026, 4:00 PM EDT
0.2574
+0.0074 (2.96%)
After-hours: Mar 17, 2026, 7:59 PM EDT

Plus Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
5.215.824.910.22-
Revenue Growth (YoY)
-10.49%18.54%2093.30%--
Gross Profit
5.215.824.910.22-
Selling, General & Admin
12.139.948.5410.246.85
Research & Development
8.3810.589.699.75.57
Total Operating Expenses
20.5120.5218.2319.9412.43
Operating Income
-15.3-14.7-13.32-19.71-12.43
Interest Income
0.120.270.40.150.02
Interest Expense
-3.61-3.72-0.4-0.71-0.93
Other Non-Operating Income (Expense)
-3.65.17-0-0.06
Total Non-Operating Income (Expense)
-7.091.720.01-0.56-0.97
Pretax Income
-22.39-12.98-13.32-20.28-13.4
Net Income
-22.39-12.98-13.32-20.28-13.4
Net Income to Common
-22.39-12.98-13.32-20.28-13.4
Shares Outstanding (Basic)
787321
Shares Outstanding (Diluted)
788321
Shares Change (YoY)
910.35%145.18%79.45%117.18%173.03%
EPS (Basic)
-0.29-1.95-4.24-11.58-16.63
EPS (Diluted)
-0.29-2.34-4.24-11.58-16.63
Free Cash Flow
-20.84-10.7-12.85-12.97-13.01
Free Cash Flow Per Share
-0.27-1.39-4.09-7.41-16.14
Gross Margin
100.00%100.00%100.00%100.00%-
Operating Margin
-293.46%-252.32%-271.14%-8800.00%-
Profit Margin
-429.43%-222.84%-271.04%-9051.34%-
FCF Margin
-399.81%-183.72%-261.57%-5791.07%-
EBITDA
-14.85-13.82-12.69-19.09-11.8
EBITDA Margin
-284.92%-237.35%-258.36%-8523.66%-
EBIT
-15.3-14.7-13.32-19.71-12.43
EBIT Margin
-293.46%-252.32%-271.14%-8800.00%-
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q